An observational study in COVID-19, sponsored by Euresist Network GEIE. Recruiting at 7 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-09-19.
Sponsored by Euresist Network GEIE · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 392 studies in COVID-19 with a site in Italy — 37 open to participants now, 46 under way, 7 of them phase 3. COVID-19 · Italy.
Among the 392 studies in COVID-19 with a site in Italy, this one is the 38th largest by planned enrollment of the 238 observational ones that give a count, is one of 36 that started in 2022, is one of 238 observational ones, reaches primary completion later than 27 of the 45 other live ones, and was the 323rd registered.
7,996 studies on the registry are indexed under COVID-19; 469 are open to participants now.
Browse COVID-19 studies →37 of the 392 studies in COVID-19 with a site in Italy are open now. Recruiting first, the newest first:
Douglas D. Fraser · Sites in Italy, United States, Brazil and 4 more countries
Ages 18–65
Azienda USL Reggio Emilia - IRCCS · Sites in Italy
Ages 18–99 · Women only
Merck Sharp & Dohme LLC · Sites in Italy, United States, Argentina and 21 more countries
Ages 18+
IRCCS Sacro Cuore Don Calabria di Negrar · Sites in Italy
Ages 18+ · Healthy volunteers
Gruppo Italiano Malattie EMatologiche dell'Adulto · Sites in Italy
Ages 18+
A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →
Of the 356 COVID-19 studies recruiting now, 205 (58%) set no upper age limit and 84 (24%) stop at 75 or younger; 90 take children under 18; 135 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
392 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 53 · Phase 3 53 · Phase 4 3
First in 2009; this study’s year is marked. 36 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 1,800 is above the median of 268 across 3,209 observational studies indexed under COVID-19.
Median enrollment 100 across the 153 interventional studies, 251 across the 238 observational. Of the 235 that completed or were terminated, 29 (12%) have results posted.
This tab as a report to print or save as PDF → With an account.
43 of 392 have an industry lead sponsor. The 10 most frequent:
Euresist Network GEIE is the lead sponsor of 6 studies on the registry; 5 are open to participants now.
Euresist Network GEIE has 3 studies filed under COVID-19 — fewer than ten, so there is no comparison to draw.
7 of the studies in COVID-19 with a site in Italy that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06928272Phase 3Douglas D. FraserLong Covid (LC)-REVITALIZE - A Long Covid Repurposed Drug Study | 2026-12 |
| NCT05624450Phase 3AstraZenecaEfficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen | 2027-11-04 |
| NCT05587894ANRS, Emerging Infectious DiseasesOPtimisation of Antiviral Therapy in Immunocompromised COVID-19 Patients: a Randomized Factorial Controlled Strategy Trial | 2026-12-31 |
| NCT05188612University of BolognaInternational Survey of Acute Coronavirus Syndromes-COVID-19 | 2026-12-31 |
| NCT06070961Fondazione Italiana Linfomi - ETSProspective Biological Study to Evaluate the Persistence of COVID-19 Vaccine and Other Vaccines'-Induced Immune Responses in Follicular Lymphoma Patients Undergoing Frontline Induction Immuno-chemotherapy and Anti-CD20 Maintenance | 2027-05 |
Add all 7 to your calendar (.ics) → With an account.
Among the 392 studies in COVID-19 with a site in Italy, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The WP3 healthcare workers cohort in EuCARE is an observational multicentre study including collection of retrospective (historical) and prospective data and sample collection from health care workers with either a vaccination or a confirmed SARS-CoV-2 infection. Samples from HCW are sent to central laboratories for WP2 study were the impact of different variants in humoral and cellular immunity is to be analysed by biostatistical methods and with artificial intelligence in WP5. This analysis will focus on the impact on vaccine escape of viral variants / viral sequences as well as on any escape from any combination of natural and vaccine induced immunity. Eight countries will participate (Portugal, Italy, Germany, Lithuania, Georgia, Russia, Vietnam and Mexico).
Background: Protection from SARS-CoV-2 infection is known to occur soon after vaccination or natural disease, fading over time. Although protection from serious illness does occur, protection from infection is insufficient and the impact of each variant and of each vaccine or vaccine schedule is a matter of continuous study. Recruiting participants from countries with different vaccines and vaccine schedules is of upmost importance to analyse these relationships and breakthrough infections. Study objectives: The EuCARE-HCW study contributes with data and samples from
HCW to EuCARE-IMMUNITY study that will analyse the NtAb and CMI to different SARS- CoV-2 variants following any combination of natural infection and vaccination. Specific
objectives include:
Sample preparation, storage and shipment to central EuCARE laboratories where WP2 study group will analyse natural and artificial immunity to SARS-CoV-2 variants (EuCARE-IMMUNITY), namely:
To accomplish the above objectives, WP2 will test:
For each subject baseline will be the occurrence of the first known immunization event, either natural infection or vaccination. The follow-up is planned to last 24 months with respect to this baseline.
Health CareWorkers can be enrolled in the category of:
(i) vaccination not followed by any later infection, (ii) infection followed by vaccination and (iii) vaccination followed by infection. However, infections diagnosed during the first wave of the epidemic are suitable for the analysis of natural immunity to SARS-CoV-2 because vaccination was administered several months later.
Inclusion Criteria:
The study subjects will be selected based on the following inclusion criteria:
Exclusion Criteria: NONE
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adult (\>18 years) HCW with mandatory information on their SARS-CoV-2 infection and vaccination status. For those with a history of SARS-CoV-2 infection, diagnosis obtained by detection of SARS-CoV-2 RNA
Other: Follow up of the first known immunization event
The baseline for enrolment into the study is defined by the occurrence of the first known immunization event, either natural infection or vaccination. The follow-up is planned to last 24 months with respect to this baseline. In subjects with natural infection, the viral variant must be determined for each prospective case by analysis of a nasopharyngeal swab obtained as soon as possible at diagnosis. For historical cases where the variant was not determined and a contemporary nasopharyngeal swab has not been stored, the viral variant may be inferred when a specific variant was dominating the geographic area according to official records available at local health agencies. However, the variant assignment will be labelled as putative, rather than proved. HCWs can be enrolled in the category of: (i) vaccination not followed by any later infection, (ii) infection followed by vaccination and (iii) vaccination followed by infection.
Number of HCW involved in the study
To collect the higher possible number of data and biological materials from the HCWs of the participating Units
Time frame: through study completion, an average of 3 years
Plan to share: Yes — The study is part of a project funded by the European Commission and the project agreement with theCommission affirms that the data and the results will be publi
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Time frame: AFTER THE STUDY END NO TIME LIMIT WAS FIXED
Access criteria: REQUEST TO THE STUDY COORDINATOR OR TO THE PROJECTPARTNERS
Data sharing details ↗ · eucareresearch.eu
No publications or documents are linked to this record.
Started Apr 2022 (actual). Primary completion is estimated for Dec 2025, 44 months after the start.
Of 1,640 non-industry observational studies under COVID-19, half reached primary completion within 14 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 30. This study's planned 44 months is above that.
Counting every sponsor, half of 1,774 studies reached it within 13 months; a quarter within 5 and three quarters within 29.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Euresist Network GEIE